Two new antithrombotic agents (fondaparinux and ximelagatran) and their implications in anesthesia

Canadian Journal of Anesthesia

Volumn 49, Issue 6, 2002, Pages

  de Moerloose, Philippe ^a   Boehlen, Françoise ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIDOTE; ANTIVITAMIN K; ARGATROBAN; EFEGATRAN; ENOXAPARIN; FONDAPARINUX; FRESH FROZEN PLASMA; HEPARIN; HIRUDIN; HIRULOG; INOGATRAN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; PROTAMINE; PROTHROMBIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN INHIBITOR; XIMELAGATRAN; AZETIDINE DERIVATIVE; BENZYLAMINE DERIVATIVE; BLOOD CLOTTING FACTOR 10; FIBRINOLYTIC AGENT; POLYSACCHARIDE; THROMBIN;

ANESTHESIA INDUCTION; ANESTHESIST; ARTICLE; BLEEDING; CLINICAL STUDY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; HEART INFARCTION; HUMAN; LABORATORY TEST; LUNG EMBOLISM; ORTHOPEDIC SURGERY; PATIENT MONITORING; PRIORITY JOURNAL; REGIONAL ANESTHESIA; THROMBOCYTOPENIA; THROMBOEMBOLISM; DRUG ANTAGONISM; REVIEW;

ANESTHESIA, CONDUCTION; AZETIDINES; FACTOR X; FIBRINOLYTIC AGENTS; HUMAN; POLYSACCHARIDES; THROMBIN; BENZYLAMINES; HUMANS;

EID: 0036600198     PISSN: 0832610X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Mortality by cause for eight regions of the world: Global burden of disease study
2. New anticoagulant drugs
3. Fondaparinux sodium: A selective inhibitor of factor Xa
4. Efficacy of the first synthetic factor Xa inhibitor, pentasaccharide Org31540/SR90107A versus low molecular weight heparin in the prevention of venous thromboembolism following elective hip replacement surgery. The EPHESUS study
5. Efficacy of the first synthetic factor Xa inhibitor, pentasaccharide Org31540/SR90107A versus low molecular weight heparin in the prevention of venous thromboembolism following elective major knee surgery. The PENTATHLON 2000 study
6. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip fracture surgery
7. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery
8. A synthetic pentasaccharide for the prevention of thrombosis after total hip replacement
9. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/Org31540) with pure anti-factor Xa activity: A phase II evaluation
10. A synthetic factor Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study
11. Pharmacokinetics of an emerging class of anticoagulant/antithrombotic drugs. A review of small-molecule thrombin inhibitors
12. Biologic rationale for the therapeutic role of specific antithombins
13. Direct thrombin inhibitors in acute coronary syndromes: Principal results of a meta-analysis based on individual patients' data
14. Comparision of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement, a phase 2 dose-finding study
15. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO 1
16. The oral direct thrombin inhibitor ximelagatran (pINN, formerly H376/95) and its subcutaneous form melagatran compared with enoxaparin as thromboprophylaxis after total hip or total knee replacement (METHRO III)
17. Effect of melagatran on prothrombin time assays depends on the sensitivity of the thromboplastin and the final dilution of the plasma sample
18. Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor